Compare GSK Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AUROBINDO PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AUROBINDO PHARMA GSK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 51.1 16.8 304.3% View Chart
P/BV x 11.5 3.6 317.2% View Chart
Dividend Yield % 1.4 0.3 473.9%  

Financials

 GSK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
GSK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,595830 433.1%   
Low Rs1,253527 237.7%   
Sales per share (Unadj.) Rs184.7333.9 55.3%  
Earnings per share (Unadj.) Rs26.340.4 65.2%  
Cash flow per share (Unadj.) Rs29.251.8 56.3%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.80.4 223.9%  
Book value per share (Unadj.) Rs126.3237.1 53.3%  
Shares outstanding (eoy) m169.40585.91 28.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x13.12.0 645.9%   
Avg P/E ratio x92.216.8 548.3%  
P/CF ratio (eoy) x83.113.1 634.0%  
Price / Book Value ratio x19.22.9 670.5%  
Dividend payout %76.16.2 1,227.9%   
Avg Mkt Cap Rs m410,626397,569 103.3%   
No. of employees `0005.017.9 27.8%   
Total wages/salary Rs m5,37225,849 20.8%   
Avg. sales/employee Rs Th6,306.710,956.9 57.6%   
Avg. wages/employee Rs Th1,083.11,447.7 74.8%   
Avg. net profit/employee Rs Th898.01,324.3 67.8%   
INCOME DATA
Net Sales Rs m31,281195,636 16.0%  
Other income Rs m1,0231,553 65.9%   
Total revenues Rs m32,304197,189 16.4%   
Gross profit Rs m6,00939,519 15.2%  
Depreciation Rs m4866,680 7.3%   
Interest Rs m62,626 0.2%   
Profit before tax Rs m6,54031,767 20.6%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m287-881 -32.6%   
Tax Rs m2,3737,269 32.6%   
Profit after tax Rs m4,45423,645 18.8%  
Gross profit margin %19.220.2 95.1%  
Effective tax rate %36.322.9 158.6%   
Net profit margin %14.212.1 117.8%  
BALANCE SHEET DATA
Current assets Rs m20,061153,645 13.1%   
Current liabilities Rs m14,543120,429 12.1%   
Net working cap to sales %17.617.0 103.9%  
Current ratio x1.41.3 108.1%  
Inventory Days Days57135 42.0%  
Debtors Days Days1464 22.1%  
Net fixed assets Rs m14,343103,909 13.8%   
Share capital Rs m1,694586 289.1%   
"Free" reserves Rs m19,704138,322 14.2%   
Net worth Rs m21,398138,908 15.4%   
Long term debt Rs m21,800 0.1%   
Total assets Rs m39,113264,544 14.8%  
Interest coverage x1,091.013.1 8,330.1%   
Debt to equity ratio x00 0.7%  
Sales to assets ratio x0.80.7 108.1%   
Return on assets %11.49.9 114.8%  
Return on equity %20.817.0 122.3%  
Return on capital %31.923.8 134.0%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m53497,316 0.5%   
Fx outflow Rs m7,09140,589 17.5%   
Net fx Rs m-6,55756,727 -11.6%   
CASH FLOW
From Operations Rs m3,99416,220 24.6%  
From Investments Rs m-1,433-28,768 5.0%  
From Financial Activity Rs m-3,58419,191 -18.7%  
Net Cashflow Rs m-1,0236,656 -15.4%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.0 128.3%  
FIIs % 23.8 27.7 85.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   102,036 69,601 146.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PFIZER  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH  TORRENT PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 243 Points, Upcoming IPOs, NTPC-GAIL Share Purchase Agreement, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed huge buying interest during the extended closing hours yesterday and ended on a strong note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Feb 24, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS